Author: Zara Puckrin

Marketing Manager at REPROCELL
Zara is a GCU graduate based at our Glasgow office. She loves minimalism, marketing and molecular biology. You can contact her on LinkedIn.

5 ways SNIPER can enhance your CRISPR gene editing

Most biologists are familiar with the precision gene editing system CRISPR. But what about SNIPER? SNIPER is a digital PCR (dPCR) and culture-based screening technology that has the power to enhance CRISPR-Cas9 gene editing – enabling multiplex gene modification, biallelic gene insertions and increased screening efficiency. Read on to find out more about how SNIPER can enhance your precision gene editing protocols and save you time, money and effort.

Continue reading 

How to determine CRISPR gene editing success in 2 weeks

Imagine CRISPR – but more efficient, reliable and flexible. SNIPER works in synergy with the CRISPR-Cas9 system to fulfill even the most challenging gene editing projects – including biallelic modifications, single base-pair changes and large DNA insertions. Read on to discover four examples of CRISPR-SNIPER in action.

Continue reading 

PRESS RELEASE: ABLE Biott Bioreactors now available in Europe

The lab-scale system will allow researchers to study and culture stem cells in suspension

Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor series for stem cell culture in 11 European countries*. The ABLE Biott Bioreactor System is a lab-scaled bioreactor that offers a new way for stem cell researchers to study and culture pluripotent stem cells.

We are excited to offer our customers the chance to access this innovative new bioreactor, which is ideal for the culture of pluripotent stem cells” said Dr David Bunton, CEO at REPROCELL Europe Ltd. “The product has been rapidly and widely adopted by stem cell scientists in Japan and the US, with the recent CE marking now enabling its use in Europe”.

Continue reading 

Improving patient outcomes through collaboration

The return on R&D investments in the UK is at its lowest rate in nine years, despite Britain’s global presence in science, technology and health. Pharmaceutical attrition rates continue to rise, and the UK biotech landscape remains fragmented. Medicines Discovery Catapult (MDC) aims to connect the UK R&D community more effectively by putting the patient at the heart of the drug discovery process. As part of our collaboration with the MDC, REPROCELL have pledged to provide custom drug discovery assays using live human tissues.

Continue reading 

From Frying-Pan to Fire

How can industry inspire the next generation of life science professionals?  Summer intern Zara Puckrin describes the challenges faced by today’s graduates and explains how REPROCELL have helped her to bridge the gap between university and work.

Continue reading 

The Human Touch: meeting clinical needs in IBD research

There is a clinical need for novel therapies in Inflammatory Bowel Disease. Current research is however limited by models which do not physiologically mimic the disease in humans. REPROCELL’s Human IBD Fresh Tissue Assay is the most clinically relevant IBD model on the market and the only commercially available assay of its kind.

Continue reading 

Characterization of iPSCs by Immunocytochemistry

As part of our contract services at REPROCELL, we offer induced pluripotent stem cell (iPSC) characterization by immunocytochemistry (ICC). Planning ICC can be tricky, as it requires careful selection of compatible antibodies and fluorochromes. However, if successful, the results are fantastic! Don’t waste valuable research time performing ICC, and let our experts do the work for you!

Continue reading